Stephen Rusckowski

Dec 15, 2016

Quest Diagnostics has appointed Stephen Rusckowski as the chairman of its board of directors. Rusckowski succeeds Daniel Stanzione, who will be staying on as lead independent director. Rusckowski joined Quest in 2012 and continues to serve as president and CEO.

More Like This

Mar 12, 2018

Phil Febbo

Illumina has appointed Phil Febbo as chief medical officer. Starting March 26, 2018, Febbo will be responsible for developing and executing on Illumina's strategy to drive genomic testing into healthcare practice.

Prior to Joining Illumina, Febbo has served as CMO at Genomic Health, and before that he served as professor of medicine and urology at the University of California, San Francisco, where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer. While at UCSF, Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology. He holds a BA degree in biology from Dartmouth College, received his MD at UCSF, and completed his internal medicine residency at the Brigham and Women's Hospital. 

Mar 07, 2018

Lee-Jen Wei

Lee-Jen Wei was appointed to the scientific advisory board of VolitionRx. Wei is a professor of biostatistics at Harvard University where his research focused mainly on developing statistical methods for designing and analyzing clinical trials. He has developed numerous novel and widely used statistical methods.

Mar 07, 2018

Paul Limburg

Exact Sciences has appointed Paul Limburg as co-chief medical officer. Limburg is a gastroenterologist and a professor of medicine at the Mayo Clinic, and serves as a co-leader of the Cancer Prevention and Control program within the Mayo Clinic Cancer Center. While at Mayo, he has also served as medical director of its global business solutions unit, and as medical director of several of its health and well-being programs. Limburg will advise Exact Sciences on research opportunities to inform, expand, and accelerate the adoption of effective colon cancer screening options such as Cologuard. He will continue to serve as a gastroenterologist with Mayo Clinic's Division of Gastroenterology and Hepatology, co-leader of the Cancer Prevention and Control program within Mayo Clinic Cancer Center, and principal investigator for the NCI-funded cancer prevention network clinical trials consortium.

Mar 07, 2018

Michael Crossey

TriCore Reference Laboratories announced Michael Crossey has been appointed CEO and president. Crossey has been serving as interim CEO since the departure of previous CEO Khosrow Shotorbani. Before serving as interim CEO, Crossey was TriCore's chief medical officer. He has worked for TriCore in various roles for 20 years

Mar 06, 2018

Jimmy Cerveaux, Jerry Conway

CDx Diagnostics announced the appointments of Jimmy Cerveaux as chief financial officer, and Jerry Conway as executive vice president of managed care. Cerveaux cofounded Unicity Eldercare and was an auditor and a mergers and acquisitions consutant at Ernst & Young. Conway has more than 27 years sales and executive management experience in the routine clinical and esoteric laboratory spaces, including stints at Foundation Medicine, Metamark Genetics, and Genzyme Genetics. 

Mar 06, 2018

Harry Rubash

BioDirection has appointed Harry Rubash chairman of the company's medical advisory board. Rubash has more than 20 years of experience as an orthopedic surgeon, researcher, and educator, and is currently emeritus chief of the department of orthopedic surgery at Massachusetts General Hospital, and the Edith M. Ashley professor of orthopedic surgery at Harvard Medical School. 

Mar 01, 2018

Guillaume Bouhours

BioMérieux has appointed Guillaume Bouhours as corporate vice-president, CFO, and a member of its executive committee. He replaces Claire Giraut, who is retiring, and will head the firm's finance, purchasing, and information systems departments. Bouhours was previously CFO at Faiveley Transport, a railway equipment manufacturer based in France.

Mar 01, 2018

Jeffrey Mitchell

LexaGene Holdings has appointed Jeffrey Mitchell as its chief financial officer effective immediately. 

Mitchell has more than two decades of financial and SEC experience, LexaGene said. Before joining the firm, he served in positions of increasing responsibility for Palomar Medical Technologies, including controller, director of finance, and supervisor of public-company financial reporting, audits, and financial planning and analysis.

He replaced Zula Kropivnitski.

Mar 01, 2018

Mark Klausner

Oxford Immunotec appointed Mark Klausner to its board of directors. He will also become a member of the board’s audit committee and nominating committee. 

Klausner is the co-founder and managing partner of Westwicke Partners, a capital markets advisory and investor relations firm focused on the healthcare industry. Prior to co-founding Westwicke Partners in 2006, he was a managing director in the Equity Capital Markets group at Wachovia, now Wells Fargo, from 2004 to 2006. 

Feb 28, 2018

Wes Brazel, Michael Marquez

Wes Brazell has told TearLab that he will resign from the company as chief financial officer, effective March 30, to pursue another professional opportunity. Michael Marquez, currently TearLab's senior director of finance, has been appointed by the board to be the interim CFO, effective March 30. Marquez joined TearLab in late 2015 as director of financial planning and analysis. Before that, he was at Alcon Laboratories in various finance positions. 

Feb 28, 2018

Jon Faiz Kayyem

GenMark Diagnostics' Founder Jon Faiz Kayyem is transitioning from his position as head of R&D to become a technical and strategic advisor to its management team and board of directors. Kayyem is the inventor of the firm's eSensor electronic detection technology and led the development of its ePlex multiplex platform. Kayyem noted during a company presentation Tuesday that he will now "endeavor to add value in new ways beyond ePlex."

Feb 20, 2018

Robert Hugin

Robert Hugin has resigned as a director at Danaher, following his decision to run for the US Senate representing New Jersey. He will run as a Republican against Sen. Robert Menendez, a Democrat. According to Politico, Hugin is a supporter of President Donald Trump. He was previously the executive chairman of Celgene before retiring from that position in January, and he was CEO of the company from June 2010 to March 2016.

Feb 16, 2018

John Goetz

John Goetz, the executive vice president and chief operating officer of Bio-Rad Laboratories, will retire and resign from his position effective March 30, 2018, but will remain available for consultation after his employment ends if a successor has not yet been named. Goetz has been with Bio-Rad for more than 40 years and was named COO in 2014. 

Feb 09, 2018

Eutillio Buccilli, Paul Kasian

Genetic Technologies, a Melbourne, Australia-based molecular diagnostics company, said this week that Eutillio Buccilli will step down as CEO. Buccilli joined the company in June 2014 as CFO and was appointed CEO in February 2015. Paul Kasian has been appointed interim CEO while the company undertakes an executive search for a permanent CEO.

Feb 07, 2018

Alberto Gutierrez

Alberto Gutierrez has joined NDA Partners as an expert consultant. The company provides consulting services in product development and regulation of medical products. Gutierrez is the former director, Office of In Vitro Diagnostics and Radiological Health, FDA Center for Devices and Radiological Health. He spent 25 years at the agency before leaving last September